Levosimendan Amdipharm (Levosimendan)

Levosimendan binds to troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac after‑load, which together improve overall cardiac output.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and renal/hepatic function. Typically, an initial loading infusion may be followed by a continuous infusion, but exact rates and duration are individualized and should follow local prescribing guidelines.

Safety data for levosimendan in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Unlike traditional catecholamine inotropes like dobutamine, levosimendan increases contractility by calcium sensitisation rather than raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and after‑load‑reducing effect that can be advantageous in certain heart‑failure patients.

Levosimendan Amdipharm must be stored refrigerated at 2‑8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Levosimendan is administered intravenously, usually as an initial loading infusion over 10‑15 minutes followed by a continuous infusion that may last 24 hours. Administration is performed under close hemodynamic monitoring in a hospital setting, with infusion rates adjusted according to the patient’s response.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Patients should be continuously monitored for blood pressure, heart rhythm and signs of ischemia throughout the infusion and for a period afterward.

Levosimendan is contraindicated in patients with severe baseline hypotension, uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in individuals with significant renal or hepatic impairment, and it should be avoided in patients receiving other potent vasodilators without close supervision.